Table 5.
Pharmacokinetic parameters of RES after tail vein administration in rats (data mean ± SD, n = 6).
| Pharmacokinetic parameters | GL-HSA-RES-NPs | Resveratrol suspension |
|---|---|---|
| AUC0→t (mg/L·h) | 4.67 ± 0.53 | 1.10 ± 0.25 |
| AUC0→∞(mg/L·h) | 5.92 ± 0.61 | 1.19 ± 0.26 |
| Cmax (ng/mL) | 933 ± 76.64 | 618 ± 42.54 |
| Tmax (h) | 0.17 ± 0.01 | 0.25 ± 0.01 |
| t1/2 (h) | 11.05 ± 2.24 | 9.37 ± 2.14 |
| MRT (h) | 8.11 ± 1.53 | 4.69 ± 0.067 |
| CLz (L/h/kg) | 1.01 ± 0.23 | 5.02 ± 0.58 |
| Vz (L/kg) | 16.14 ± 2.46 | 67.86 ± 11.23 |
AUC0→t, The area under the blood concentration time curve from 0 to the last selected time point; AUC(0–∞), The area under the blood concentration time curve during the period from 0 to infinity; Cmax: Maximum plasma concentration of resveratrol after administration; Tmax: is the time when Cmax appears; t1/2: elimination half-life; MRT: mean residence time; CLz: total clearance; Vz: volume of distribution at terminal state.